Enliven Therapeutics, Inc. (ELVN) - Stock Analysis
Last updated: Jun 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Cash Cushion • No Revenue • Heavy R&D ELVN has an exceptionally strong cash-rich balance sheet with minimal liabilities, but its lack of revenue, ongoing losses, negative free cash flow, and premium valuation make it a speculative, development-stage investment.
Price Behavior
Key Price Behavior Insights: • Trend Reversal • Near Resistance • Volatile Bounce Support Level: $42.30-$42.60 Resistance Level: $46.13 ELVN has rebounded sharply over the last month and is holding above nearby support, but the move remains volatile and capped near $46.13 resistance.
Sentiment & News
Key News Insights: • Phase 1 efficacy • FDA alignment • Capital raise Enliven delivered encouraging Phase 1 ELVN-001 results and FDA-aligned Phase 3 plans, while a completed upsized offering strengthened funding.
AI Summary
ELVN has moved from a speculative early-data biotech into a better-funded but more diluted pivotal-stage story, so the investable question is now whether ENABLE-2 can validate the Phase 1 CML signal cleanly enough to justify the current premium valuation without further share-count erosion.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |